Recently, in 2024, the same group of authors reported a 64-year-old woman with isocitrate dehydrogenase (IDH)-wildtype GBM who underwent the standard treatment protocol together with an intensive, multimodal KD program for 3 years. The gene discussed is IDH3A; the disease is glioblastoma.